Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Efficacy and Toxicity of Frontline Ponatinib Plus Blinatumomab for Adult Ph+ ALL Patients of All Ages. Intermediate Analysis of the Gimema ALL2820

Blood (2024) 144 (Supplement 1): 835.

https://doi.org/10.1182/blood-2024-207892

Published: 2024

Journal Articles

CD38 Expression As an Additional Prognostic Marker in Mantle Cell Lymphoma

Matteo D'Addona, Luca Pezzullo, Valentina Giudice, Danilo De Novellis, Idalucia Ferrara, Raffaele Fontana, Roberto Guariglia, Serena Luponio, Laura Mettivier, Maria Carmen Martorelli, Andrea Gigantiello, Denise Morini, Michela Rizzo, Maria Teresa Buonanno, Giuseppe Ciancia, Marisa Gorrese, Bianca Serio, Carmine Selleri

Blood (2024) 144 (Supplement 1): 6250.

https://doi.org/10.1182/blood-2024-198812

Published: 2024

Journal Articles

Measurable Residual Disease Monitoring for Philadelphia Positive Acute Lymphoblastic Leukemia (Ph+ALL) in the Setting of the Gimema ALL2820 Trial

Blood (2024) 144 (Supplement 1): 2836.

https://doi.org/10.1182/blood-2024-210731

Published: 2024

Journal Articles

Survival Analysis of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 2891.

https://doi.org/10.1182/blood-2024-207842

Published: 2024

Journal Articles

Final Analysis for the Primary End-Point of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 1536.

https://doi.org/10.1182/blood-2023-184678

Published: 2023

Journal Articles

Novel Gene Mutations Associated with Disease-Free Survival in Elderly Patients with Acute Myeloid Leukemia Receiving First-Line Induction-Consolidation with or without Azacitidine Post-Remission Treatment

Blood (2023) 142 (Supplement 1): 6046.

https://doi.org/10.1182/blood-2023-186325

Published: 2023

Journal Articles

Low-Density Granulocytes Are Decreased in Acute Myeloid Leukemia and in Myelodysplastic Syndromes with Negative Prognostic Factors

Valentina Giudice, Marisa Gorrese, Idalucia Ferrara, Rita Pepe, Angela Bertolini, Rosa Vitolo, Rossella Marcucci, Paola Manzo, Matteo D'Addona, Maria Carmen Martorelli, Maria Teresa Buonanno, Maddalena Langella, Bianca Serio, Carmine Selleri

Blood (2021) 138 (Supplement 1): 4448.

https://doi.org/10.1182/blood-2021-150727

Published: 2021

Journal Articles

Hemopoiesis and Immune Cell Perturbations during Venetoclax Plus Azacytidine Treatment in Acute Myeloid Leukemia

Valentina Giudice, Idalucia Ferrara, Marisa Gorrese, Francesca D'Alto, Roberto Guariglia, Serena Luponio, Luca Pezzullo, Laura Mettivier, Angela Bertolini, Matteo D'Addona, Danilo De Novellis, Bianca Cuffa, Bianca Serio, Carmine Selleri

Blood (2021) 138 (Supplement 1): 4339.

https://doi.org/10.1182/blood-2021-150484

Published: 2021

Journal Articles

The Role of B Regulatory Cells in the Immunological Escape of Tumor Cells in Hodgkin Lymphoma

Valentina Giudice, MD, Monia Rocco, PhD, Giancarlo Villani, Rosa Rosamilio, MD, Luca Pezzullo, MD, Bianca Serio, MD, Idalucia Ferrara, MD, Carmine Selleri, MD

Blood (2016) 128 (22): 1768.

https://doi.org/10.1182/blood.V128.22.1768.1768

Published: 2016

Journal Articles

How to Improve the Definition of Chronic Lymphocytic Leukemia Outcome Using a Simple Flow Cytometric Score Based on CD49d and Homing Marker Expression

Valentina Giudice, MD, Monia Rocco, PhD, Luca Pezzullo, MD, Giancarlo Villani, Rosa Rosamilio, MD, Luigi Marino, Silvana Annunziata, MD, Raffaele Fontana, MD, Idalucia Ferrara, MD, Bianca Serio, MD, Carmine Selleri, MD

Blood (2016) 128 (22): 5567.

https://doi.org/10.1182/blood.V128.22.5567.5567

Published: 2016

Journal Articles

Induction Therapy With Continuous Alternate-Day Low Dose Lenalidomide Combined With Low-Dose Prednisone In Octogenarian Multiple Myeloma Patients

Luca Pezzullo, MD, Bianca Serio, MD, Raffaele Fontana, MD,, Idalucia Ferrara, MD, Mariarosaria Sessa, Valentina Giudice, Giancarlo Villani, Monia Rocco, Carmine Selleri, MD

Blood (2013) 122 (21): 5394.

https://doi.org/10.1182/blood.V122.21.5394.5394

Published: 2013

Journal Articles

Cytomegalovirus Reactivation Prophylaxis With Low Dose Valgancyclovir After Hematopoietic Stem Cell Transplantation

Bianca Serio, MD, Luca Pezzullo, MD, Raffaele Fontana, MD, Silvana Annunziata, MD, Rosa Rosamilio, Idalucia Ferrara, MD, Monia Rocco, Valentina Giudice, Mariarosaria Sessa, Ciro De Luca, Carmine Selleri, MD

Blood (2013) 122 (21): 4578.

https://doi.org/10.1182/blood.V122.21.4578.4578

Published: 2013

Journal Articles

Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab

Blood (2009) 113 (17): 4094–4100.

https://doi.org/10.1182/blood-2008-11-189944

Published: 2009

Journal Articles

Role of the Urokinase Receptor (uPAR) in the Cross-Talk of Hematopoietic Stem Cells with the Bone Marrow Microenvironment

Nunzia Montuori, PhD, Patrizia Ricci, Bianca Serio, Valeria Visconte, PhD, Claudio La Penna, Ada Pesapane, Antonio M. Risitano, MD, PhD, Bruno Rotoli, Guido Rossi, Pia Ragno, PhD, Carmine Selleri

Blood (2008) 112 (11): 324.

https://doi.org/10.1182/blood.V112.11.324.324

Published: 2008

Journal Articles

Subcutaneous Alemtuzumab Is a Safe and Effective Treatment for Global or Single-Lineage Immune-Mediated Marrow Failures: a Survey from the EBMT-WPSAA

Antonio M. Risitano, MD, PhD, Elisa Seneca, Ludovica Marando, Bianca Serio, Carmine Selleri, Giulia Scalia, Luigi Del Vecchio, MD, Annapaola Iori, M.D., Alexander Kulagin, Sebastien Maury, Joerg Halter, Vikas Gupta, MD, MRCP, MRCPath, Andrea Bacigalupo, MD, Gerard Socié, Andre Tichelli, Judith Marsh, Hubert Schrezenmeier, Jakob R. Passweg, MD, MS, Bruno Rotoli

Blood (2008) 112 (11): 1042.

https://doi.org/10.1182/blood.V112.11.1042.1042

Published: 2008

Journal Articles

Permissive Conditions for Evolution of PNH Clones Are Characterized by Overproduction of IFN-γ by Clonal CD4 and CD8 T Cells, Fas-L by CTLs, and Promoted by Immunogenetic Background

Michael Clemente, Heather Cazzolli, Anna Jankowska, Christine O’Keefe, Bianca Serio, Susan Nyland, Marcin Wlodarski, PK Epling-Burnette, Thomas Loughran, Alan List, Ronald Paquette, Jaroslaw Maciejewski

Blood (2008) 112 (11): 4116.

https://doi.org/10.1182/blood.V112.11.4116.4116

Published: 2008

Journal Articles

C3-Mediated Extravascular Hemolysis as Additional Mechanism of Disease in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated by the Complent Inhibitor Eculizumab

Blood (2008) 112 (11): 485.

https://doi.org/10.1182/blood.V112.11.485.485

Published: 2008

Journal Articles

Analysis of Immunogenetic Factors in Myelodysplastic Syndromes (MDS) Reveals Potential Pathogenic Role Cytokine Genotypes Such as TGF-β.

Bianca Serio, MD, Ramon Tiu, MD, Ania Jankowska, MS, Zach Nearman, BS, Christine O’Keefe, PhD, Mikkael A. Sekeres, MD, MS, Jaroslaw M.D. Maciejewski, MD, PhD

Blood (2007) 110 (11): 2446.

https://doi.org/10.1182/blood.V110.11.2446.2446

Published: 2007

Journal Articles

Phospho-IkappaB Is Abnormally Expressed in Bone Marrow of CMML Patients.

Ziad Peerwani, MD, Ramon Tiu, MD, Bianca Serio, MD, Andrew Schade, MD, PhD, Jaroslaw P. Maciejewski, MD, PhD, Eric D. Hsi, MD

Blood (2007) 110 (11): 2450.

https://doi.org/10.1182/blood.V110.11.2450.2450

Published: 2007

Journal Articles

Subcutaneous Alemtuzumab Is Safe and Effective for Treatment of Global or Single-Lineage Immune-Mediated Marrow Failure: A Pilot Study.

Antonio M. Risitano, MD, PhD, Carmine Selleri, MD, Bianca Serio, MD, Ludovica Marando, Andrea Camera, MD, Lucio Catalano, MD, Giulia Scalia, PhD, Luigi Del Vecchio, MD, Bruno Rotoli, MD

Blood (2007) 110 (11): 1692.

https://doi.org/10.1182/blood.V110.11.1692.1692

Published: 2007

NARROW

Efficacy and Toxicity of Frontline Ponatinib Plus Blinatumomab for Adult Ph+ ALL Patients of All Ages. Intermediate Analysis of the Gimema ALL2820

CD38 Expression As an Additional Prognostic Marker in Mantle Cell Lymphoma

Measurable Residual Disease Monitoring for Philadelphia Positive Acute Lymphoblastic Leukemia (Ph+ALL) in the Setting of the Gimema ALL2820 Trial

Survival Analysis of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Final Analysis for the Primary End-Point of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Novel Gene Mutations Associated with Disease-Free Survival in Elderly Patients with Acute Myeloid Leukemia Receiving First-Line Induction-Consolidation with or without Azacitidine Post-Remission Treatment

Low-Density Granulocytes Are Decreased in Acute Myeloid Leukemia and in Myelodysplastic Syndromes with Negative Prognostic Factors

Hemopoiesis and Immune Cell Perturbations during Venetoclax Plus Azacytidine Treatment in Acute Myeloid Leukemia

The Role of B Regulatory Cells in the Immunological Escape of Tumor Cells in Hodgkin Lymphoma

How to Improve the Definition of Chronic Lymphocytic Leukemia Outcome Using a Simple Flow Cytometric Score Based on CD49d and Homing Marker Expression

Induction Therapy With Continuous Alternate-Day Low Dose Lenalidomide Combined With Low-Dose Prednisone In Octogenarian Multiple Myeloma Patients

Cytomegalovirus Reactivation Prophylaxis With Low Dose Valgancyclovir After Hematopoietic Stem Cell Transplantation

Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab

Role of the Urokinase Receptor (uPAR) in the Cross-Talk of Hematopoietic Stem Cells with the Bone Marrow Microenvironment

Subcutaneous Alemtuzumab Is a Safe and Effective Treatment for Global or Single-Lineage Immune-Mediated Marrow Failures: a Survey from the EBMT-WPSAA

Permissive Conditions for Evolution of PNH Clones Are Characterized by Overproduction of IFN-γ by Clonal CD4 and CD8 T Cells, Fas-L by CTLs, and Promoted by Immunogenetic Background

C3-Mediated Extravascular Hemolysis as Additional Mechanism of Disease in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated by the Complent Inhibitor Eculizumab

Analysis of Immunogenetic Factors in Myelodysplastic Syndromes (MDS) Reveals Potential Pathogenic Role Cytokine Genotypes Such as TGF-β.

Phospho-IkappaB Is Abnormally Expressed in Bone Marrow of CMML Patients.

Subcutaneous Alemtuzumab Is Safe and Effective for Treatment of Global or Single-Lineage Immune-Mediated Marrow Failure: A Pilot Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only